Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.

Trial Profile

Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Vinflunine (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Jasint-2
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 13 Jul 2017 This trial was completed in Spain, according to European Clinical Trials Database.
    • 23 Nov 2016 This trial has been discontinued in Poland.
    • 09 Aug 2016 This trial was discontinued in Austria (End Date: 27 Jul 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top